"Arsenicals" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds that contain arsenic.
| Descriptor ID |
D001152
|
| MeSH Number(s) |
D01.075 D02.691.088
|
| Concept/Terms |
Arsenicals- Arsenicals
- Arsenic Compounds
- Compounds, Arsenic
|
Below are MeSH descriptors whose meaning is more general than "Arsenicals".
Below are MeSH descriptors whose meaning is more specific than "Arsenicals".
This graph shows the total number of publications written about "Arsenicals" by people in this website by year, and whether "Arsenicals" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 1 | 2 |
| 2005 | 2 | 0 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Arsenicals" by people in Profiles.
-
Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation. Clin Adv Hematol Oncol. 2007 Apr; 5(4):320-3; discussion 323-4.
-
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1249-69.
-
Acute lung injury induced by arsenic trioxide in a patient with refractory myelodysplastic syndrome. J Crit Care. 2005 Mar; 20(1):111-3.
-
Arsenic trioxide represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem. 2005 Mar 01; 94(4):695-707.
-
L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem. 2004 Oct 01; 93(2):257-70.
-
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res. 2004 Aug; 28(8):791-803.